An individual development theme concerning AGS-003, for which the Phase 3 trial continued after consultation with the FDA following a recommendation to discontinue it by the independent data monitoring committee, but the licensing agreement ended after the licensee, Argos, went bankrupt and approval was obtained to reject the contract.